Immune activation alters cellular and humoral responses to yellow fever 17D vaccine

Muyanja, Enoch; Ssemaganda, Aloysius; Ngauv, Pearline; Cubas, Rafael; Perrin, Helene; Srinivasan, Divya; Canderan, Glenda; Lawson, Benton; Kopycinski, Jakub; Graham, Amanda S.; Rowe, Dawne K.; Smith, Michaela J.; Isern, Sharon; Michael, Scott; Silvestri, Guido; Vanderford, Thomas H.; Castro, Erika; Pantaleo, Giuseppe; Singer, Joel; Gillmour, Jill
July 2014
Journal of Clinical Investigation;Jul2014, Vol. 124 Issue 7, p3147
Academic Journal
Background. Defining the parameters that modulate vaccine responses in African populations will be imperative to design effective vaccines for protection against HIV, malaria, tuberculosis, and dengue virus infections. This study aimed to evaluate the contribution of the patient-specific immune microenvironment to the response to the licensed yellow fever vaccine 17D (YF-17D) in an African cohort. Methods. We compared responses to YP-17D in 50 volunteers in Entebbe, Uganda, and 50 volunteers in Lausanne, Switzerland. We measured the CD8+ T cell and B cell responses induced by YF-17D and correlated them with immune parameters analyzed by flow cytometry prior to vaccination. Results. We showed that YF-17D-induced CD8+ T cell and B cell responses were substantially lower in immunized individuals from Entebbe compared with immunized individuals from Lausanne. The impaired vaccine response in the Entebbe cohort associated with reduced YF-17D replication. Prior to vaccination, we observed higher frequencies of exhausted and activated NK cells, differentiated T and B cell subsets and proinflammatory monocytes, suggesting an activated immune microenvironment in the Entebbe volunteers. Interestingly, activation of CD8+ T cells and B cells as well as proinflammatory monocytes at baseline negatively correlated with YF-17D-neutralizing antibody titers after vaccination. Additionally, memory T and B cell responses in preimmunized volunteers exhibited reduced persistence in the Entebbe cohort but were boosted by a second vaccination. Conclusion. Together, these results demonstrate that an activated immune microenvironment prior to vaccination impedes efficacy of the YF-17D vaccine in an African cohort and suggest that vaccine regimens may need to be boosted in African populations to achieve efficient immunity. Trial registration. Registration is not required for observational studies. Funding. This study was funded by Canada's Global Health Research Initiative, Defense Threat Reduction Agency, National Institute of Allergy and Infectious Diseases, Bill & Melinda Gates Foundation, and United States Agency for International Development.


Related Articles

  • Corrigendum.  // Journal of Clinical Investigation;Oct2014, Vol. 124 Issue 10, p4669 

    A correction to the article "Immune Activation Alters Cellular and Humoral Responses to Yellow Fever 17D Vaccine" by Enoch Muyanja, Pearline Ngauv and Rafael Cubas is presented.

  • Vaccines: Predicting immunity. Leavy, Olive // Nature Reviews Immunology;Jan2009, Vol. 9 Issue 1, p4 

    The article discusses the studies which identify the early gene signatures induced in humans vaccinated with the attenuated yellow fever vaccine YF17D. The two studies analysed total peripheral-blood mononuclear cells and determined the effects on gene expression through transcriptional...

  • A DNA Vaccine against Yellow Fever Virus: Development and Evaluation. Jr.Maciel, Milton; Cruz, Fábia da Silva Pereira; Cordeiro, Marli Tenório; da Motta, Márcia Archer; Cassemiro, Klécia Marília Soares de Melo; Maia, Rita de Cássia Carvalho; de Figueiredo, Regina Célia Bressan Queiroz; Galler, Ricardo; Freire, Marcos da Silva; August, Joseph Thomas; Marques, Ernesto T. A.; Dhalia, Rafael // PLoS Neglected Tropical Diseases;Apr2015, Vol. 9 Issue 4, p1 

    Attenuated yellow fever (YF) virus 17D/17DD vaccines are the only available protection from YF infection, which remains a significant source of morbidity and mortality in the tropical areas of the world. The attenuated YF virus vaccine, which is used worldwide, generates both long-lasting...

  • Elderly Subjects Have a Delayed Antibody Response and Prolonged Viraemia following Yellow Fever Vaccination: A Prospective Controlled Cohort Study. Roukens, Anna H.; Soonawala, Darius; Joosten, Simone A.; de Visser, Adriëtte W.; Jiang, Xiaohong; Dirksen, Kees; de Gruijter, Marjolein; van Dissel, Jaap T.; Bredenbeek, Peter J.; Visser, Leo G. // PLoS ONE;2011, Vol. 6 Issue 12, p1 

    Background: Yellow fever vaccination (YF-17D) can cause serious adverse events (SAEs). The mechanism of these SAEs is poorly understood. Older age has been identified as a risk factor. We tested the hypothesis that the humoral immune response to yellow fever vaccine develops more slowly in...

  • Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali Sidibe, Mariam; Yactayo, Sergio; Kalle, Abdoulaye; Sall, Amadou A.; Sow, Samba; Ndoutabe, Modjirom; Perea, William; Avokey, Fenella; Lewis, Rosamund F.; Veit, Olivia // Transactions of the Royal Society of Tropical Medicine & Hygiene;Jul2012, Vol. 106 Issue 7, p437 

    Abstract: The immune response to yellow fever (YF) vaccine and its safety among HIV-infected individuals living in YF endemic areas is not well understood. Following a national YF preventive immunisation campaign in Mali in April 2008, we assessed the immunogenicity and safety of 17D yellow...

  • Live Japanese encephalitis vaccine.  // Australian Prescriber;Apr2013, Vol. 36 Issue 2, p66 

    The article offers information on live Japanese encephalitis vaccine which was approved for Japanese encephalitis prevention in Australia. It says that the new drug uses yellow fever vaccine virus or strain 17D-204 as vector. It mentions that the phase III immunogenicity trail reveals that the...

  • Dissection of Antibody Specificities Induced by Yellow Fever Vaccination. Vratskikh, Oksana; Stiasny, Karin; Zlatkovic, Jürgen; Tsouchnikas, Georgios; Jarmer, Johanna; Karrer, Urs; Roggendorf, Michael; Roggendorf, Hedwig; Allwinn, Regina; Heinz, Franz X. // PLoS Pathogens;Jun2013, Vol. 9 Issue 6, p1 

    The live attenuated yellow fever (YF) vaccine has an excellent record of efficacy and one dose provides long-lasting immunity, which in many cases may last a lifetime. Vaccination stimulates strong innate and adaptive immune responses, and neutralizing antibodies are considered to be the major...

  • Intradermally Administered Yellow Fever Vaccine at Reduced Dose Induces a Protective Immune Response: A Randomized Controlled Non-Inferiority Trial. Roukens, Anna H.; Vossen, Ann C.; Bredenbeek, Peter J.; van Dissel, Jaap T.; Visser, Leo G. // PLoS ONE;2008, Vol. 3 Issue 4, p1 

    Background: Implementation of yellow fever vaccination is currently hampered by limited supply of vaccine. An alternative route of administration with reduced amounts of vaccine but without loss of vaccine efficacy would boost vaccination programmes. Methods and Findings: A randomized,...

  • Immune Response during Adverse Events after 17D-Derived Yellow Fever Vaccination in Europe. Bae, Hi-Gung; Domingo, Cristina; Tenorio, Antonio; de Ory, Fernando; Muñoz, José; Weber, Paul; Teuwen, Dirk E.; Niedrig, Matthias // Journal of Infectious Diseases;6/1/2008, Vol. 197 Issue 11, p1577 

    Background. In 1999-2000, reports of fatalities after vaccination with 17D-derived yellow fever vaccine (YEL) focused mainly on cases of YEL-associated adverse events (YEL-AEs) and YEL-associated viscerotropic disease (YEL-AVD). Here, we investigated 6 recent European cases to provide insight...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics